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The mechanism of hepatitis B virus (HBV) induced liver inflammation is not fully
elucidated. Notch signaling augmented interleukin (IL)-22 secretion in CD4+ T cells,
and Notch-IL-22 axis fine-tuned inflammatory response. We previously demonstrated
a proinflammatory role of IL-22 in HBV infection. Thus, in this study, we analyzed the
role of Notch in development of IL-22-producing cells in HBV infection by inhibition of
Notch signaling using γ-secretase inhibitor DAPT in both hydrodynamic induced HBV-
infected mouse model and in peripheral blood cells isolated from patients with HBV
infection. mRNA expressions of Notch1 and Notch2 were significantly increased in livers
and CD4+ T cells upon HBV infection. Inhibition of Notch signaling in vivo leaded to
the reduction in NKp46+ innate lymphoid cells 22 (ILC22) and lymphoid tissue inducer 4
(LTi4) cells in the liver. This process was accompanied by downregulating the expressions
of IL-22 and related proinflammatory cytokines and chemokines in the liver, as well as
blocking the recruitment of antigen-non-specific inflammatory cells into the liver and
subsequent liver injury, but did not affect HBV antigens production and IL-22 secretion
in the serum. Furthermore, IL-22 production in HBV non-specific cultured CD4+ T cells,
but not HBV-specific CD4+ T cells, was reduced in response to in vitro inhibition of
Notch signaling. In conclusion, Notch siganling appears to be an important mediator of
the liver inflammation by modulating hepatic ILC22. The potential proinflammatory effect
of Notch-mediated ILC22 may be significant for the development of new therapeutic
approaches for treatment of hepatitis B.
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INTRODUCTION
Hepatitis B virus (HBV) infection is still a severe public health problem, with ∼350 million
infections all over the world (Bitton Alaluf and Shlomai, 2016). Current therapies for chronic
hepatitis B (CHB) include interferon-α and nucleos(t)ide analogs, which could prevent the
progression to end-stage liver diseases. However, cure is rare due to the formation of covalently
closed circular DNA within the nucleus of HBV-infected hepatocytes (Zoulim et al., 2016). It is
also well accepted that clinical outcome of HBV infection results from the complicated interaction
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between virus and host immune response (Bertoletti and Ferrari,
2016; Maini and Gehring, 2016), leading to different disease
phases (Lok, 2016).Moreover, HBV infection also induces a series
of inflammation networks, which manifested as the elevation
of specific immune cell populations and molecules (Chang and
Lewin, 2007). We previously screened the expression profile of
cytokines and chemokines in CHB patients (Lian et al., 2014),
and demonstrated the predominate proinflammatory role of
interleukin (IL)-22 in HBV infection (Zhang et al., 2011).
IL-22 belongs to IL-10 superfamily of cytokines with potential
dual nature of proinflammatory and protective properties
(Dudakov et al., 2015). IL-22 was primarily produced by T-
helper (Th) 17 and Th22 cells (Perusina Lanfranca et al.,
2016), and recent studies have demonstrated a new source of
IL-22 in innate lymphoid cells (ILCs) subset, which named
as ILC22 (Spits and Di Santo, 2011; Hwang and McKenzie,
2013). Notch signaling is an evolutionally conserved intercellular
communication mechanism that controls cell fate decision and
differentiation process in a variety of cells (Osborne and Minter,
2007). The interaction between Notch and ligands results in
the cleavage of molecules in the transmembrane region by γ-
secretase, and followed by intracellular domain translocation into
the nucleus (Osborne and Minter, 2007). Increasing evidence
indicated that Notch signaling was essential not only in selection
of CD4+/CD8+ lineage choices, but also in controlling of the
effector functions of CD4+/CD8+ T cells (Maekawa et al., 2003,
2008; Radtke et al., 2004; Tsukumo and Yasutomo, 2004). More
importantly, Notch signaling up-regulated IL-22 expression in
CD4+ T cells even in STAT3-deficient manner, and this process
was due to Notch-mediated production of aryl hydrocarbon
receptor (AhR) stimulator (Alam et al., 2010).
Notch1 was found to be abundantly expressed in CHB patients
(Pei et al., 2010). Based on the regulatory mechanism of IL-
22 production by Notching signaling (Alam et al., 2010) and
the proinflammatory role of IL-22 in HBV infection (Zhang
et al., 2011), we hypothesized that Notch signaling performed
an important regulatory role for IL-22-producing cells in HBV
infection. To test this possibility, we examined the changes
in IL-22-producing cells and IL-22 expression as well as their
relationship to liver inflammation by inhibition of Notch
signaling in vivo and in vitro.
MATERIALS AND METHODS
Mice
Male BALB/c (H-2d) mice 6–8 weeks of age were purchased
from Experimental Animal Center of Fourth Military Medical
University. The experiments were performed in accordance with
the procedures approved by Animal Care and Use Committee
of Fourth Military Medical University. Mice were challenged
using a hydrodynamic transfection protocol, whereby a total of
10µg pHBV1.3, with or without 0.1mg/g of γ-secretase inhibitor
DAPT (Selleck Chemicals, Huston, TX, USA), was injected into
veins in a volumes of PBS equal to 9% of their body mass (Yang
et al., 2002; Cobleigh et al., 2010). Mice were scarified 96 h
post-transfection. Livers and serum were harvested for further
analysis.
Virological and Biochemical Assessments
Semi-quantifications of hepatitis B surface antigen (HBsAg)
and hepatitis B e antigen (HBeAg) were performed by electro-
chemiluminescence (Architect, Abbott Laboratories, and Abbott
Park, IL, USA). Alanine aminotransferase (ALT) level in the
serum was measured by Infinity ALT reagent (Thermo Electron,
Louisville, CO, USA).
Flow Cytometry
The intrahepatic lymphocytes (IHLs) were purified as described
previously (Cobleigh et al., 2010). Purified IHLs were stained
with anti-mouse CD3-PerCP Cy5.5, anti-mouse CD4-FITC,
anti-mouse CD127-PE Texas Red, anti-mouse NK1.1-PE
Cy7, anti-mouse RORγt-PE, and anti-mouse NKp46-APC (all
purchased from eBioscince, San Diego, CA, USA). Samples were
analyzed with FACS Aria II flow cytometor (BD Biosciences
Immunocytometry Systems, San Jose, CA, USA). Acquisitions
were performed with CellQuest Pro software (BD Biosciences
Immunocytometry Systems), and analyses were performed with
FlowJo version 8.7.2 for Windows (Tree Star Inc., Ashland, OR,
USA).
Subjects
A total of 45 patients with HBV infection, including 13 of
acute hepatitis B (AHB) and 32 of CHB, were enrolled in the
present study. All patients were hospitalized or followed-up
between March 2013 and June 2015 in Center for Infectious
Diseases of Tangdu Hospital. The standards of diagnoses were
made according to the diagnostic standard of Chinese Guideline
for Prevention and Treatment of Hepatitis B. Patients who
received anti-HBV agents or immunomodulatory medication 1
year before sampling were excluded. No patients were co-infected
with human immunodeficiency virus or other hepatitis viruses
or concurrently aﬄicted by immune-compromised diseases or
autoimmune disorders. For normal controls (NCs), 20 healthy
individuals with matched sex and age were also selected. The
clinical characteristics of enrolled subjects were shown inTable 1.
The study conformed to the ethical guidelines of the 1975
Declaration of Helsinki. The human study protocol was approved
by the Ethics Committee of Tangdu Hospital, and written
informed consent was obtained from each participant.
Peripheral Blood Mononuclear Cells
(PBMCs) Isolation and CD4+ T Cells
Purification
PBMCs were isolated using Ficoll-Hypaque (Sigma-Aldrich, St
Louis, MO, USA) density gradient centrifugation. CD4+ T
cells were purified using human CD4+ T cells isolation kit
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) under the
instruction from manufacturer. The purity of enriched cells for
CD4+ T cells (>95%) was determined by flow cytometry.
Cell Culture
Purified CD4+ T cells were seeded into 24-well plates with
concentration of 2 × 106/mL, and were incubated in RPMI 1640
supplemented with 10% of heat-inactivated FBS at 37◦C in a
5% CO2 environment. CD4
+ T cells were stimulated by either
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2 October 2016 | Volume 6 | Article 132
Wei et al. Notch-IL-22 Axis in HBV Infection
TABLE 1 | Clinical characteristics of enrolled subjects.
AHB CHB NCs
Cases 13 32 20
Age (year) 29.3 ± 7.5 27.5 ± 7.8 29.4 ± 4.3
Gender (Male/Female) 8/5 22/10 13/7
ALT (U/L) 1784 ± 791 149 ± 28 25 ± 8
HBsAg positive 13 32 0
HBeAg positive 8 32 0
Anti-HBe positive 5 0 0
Anti-HBc IgM positive 13 0 0
HBV DNA (log10 IU/mL) 5.32 ± 1.32 6.73 ± 2.05 N.D.
AHB, acute hepatitis B; CHB, chronic hepatitis B; NCs, normal control; N.D., not
determined.
anti-CD3 antibody (eBioscience, final concentration 1µg/mL) or
HBV core peptides pool (a total of 41 peptides, 15 amino acids of
each peptide with 5 amino acids overlapping, final concentration
10µg/mL), with or without Notch signaling inhibitor DAPT
(final concentration 75µmol/L). Cells and supernatants were
harvested 96 h post stimulation.
Real-Time Reverse-Transcript Polymerase
Chain Reaction (RT-PCR)
Total RNA was isolated from cultured CD4+ T cells or liver
of the mice using RNeasy minikit (Qiagen, Hilden, Germany)
according to the instructions from manufacture. RNA was
reversely transcribed with random hexamers using PrimeScript
RT Master Mix (TaKaRa, Dalian, China). Real-time PCR was
performed using SYBR Premix Ex Taq (TaKaRa). Relative gene
expression was quantified by ∆∆CT method using 7500 System
Sequence Detection software (Applied Biosystems, Foster, CA,
USA). The sequences of the primers were shown in Table S1.
Enzyme-Linked Immunosorbent Assay
(ELISA)
IL-22 production in the supernatants of cultured CD4+ T cells or
serum of mice were measured using commercial human/mouse
IL-22 ELISA kits (eBioscience) according to the instructions from
the manufacture.
Statistical Analysis
Statistical significance was determined by Dunn’s multiple
comparison test or Student t-test using SPSS version 19.0 for
Windows (SPSS, Chicago, IL, USA). P-values of < 0.05 were
considered to indicate a significant difference.
RESULTS
Inhibition of Notch Signaling Did Not Affect
HBV Antigens Production but Reduced
Liver Damage In vivo
We firstly measured Notch mRNA expressions in the liver of
the mice. All mice received intravenous injections of saline with
or without pHBV1.3 under hydrodynamic conditions, allowing
for transfection of hepatocytes in vivo (Cobleigh et al., 2010). A
group of mice also received hydrodynamic injection combined
with pHBV1.3 and Notch signaling inhibitor DAPT. Livers
were harvested 96 h post-injection, and Notch mRNA were
semi-quantified by RT-PCR. Both Notch1 and Notch2 mRNA
expressions were elevated in the liver of mice transfected with
pHBV1.3. There were about 10-fold and 2-fold elevations in
hepatic Notch1 and Notch2 mRNA in response to HBV plasmid
transfection, respectively (Figures 1A,B). In accordance with
the elevation of Notch1 and Notch2, HBV plasmid transfection
also induced the hepatic mRNA expression of Notch signaling
related molecules (Hes1 and Hes5) and Notch ligands [Jagged1,
Jagged2, and Delta-like 4 (Dll4)]. DAPT significantly reduced
the mRNA expressions of above molecules in the liver, which
indicated that DAPT successfully inhibited Notch signaling
in vivo (Figure S1). However, inhibition of Notch did not
downregulate HBV-induced Notch1 and Notch2 expressions in
the liver (Figures 1A,B). Furthermore, HBV plasmid transfection
induced high levels of HBsAg and HBeAg productions. Blockage
of Notch signaling by administration of DAPT did not alter
the release of the secreted viral antigens into the serum
(Figures 1C,D). Liver damage inmice that receivedHBVplasmid
transfection wasmoderate asmeasured by serumALT level, while
DAPT treatment diminished the severity of liver disease with
mild elevation of ALT in the serum (Figure 1E). However, there
were no remarkable differences among the three groups in the
serum concentration of IL-22 (Figure 1F).
We then further measured the IL-22 as well as related
cytokines and chemokines in the liver. As shown in Figure 2,
IL-22 mRNA expression were significantly elevated in the
liver with HBV plasmid hydrodynamic injection, however,
inhibition of Notch signaling remarkably reduced the IL-22
mRNA levels (Figure 2A). mRNA expressions of interferon-
γ (IFN-γ), tumor necrosis factor-α (TNF-α), CXCL9, and
CXCL10 demonstrated similar trends with IL-22 expressions.
DAPT treatment suppressed the upregulation of HBV-induced
expressions of these cytokines and chemokines (Figures 2B–E).
Inhibition of Notch Signaling Reduced the
Intrahepatic ILC22 Subsets and Blocked
Recruitment of Inflammatory Cells into the
Liver
We further investigate the changes of IL-22 secreting cells in
the liver in response to HBV infection with or without DAPT
treatment. We initially focused on the liver resident CD4+ T cell
population because Th17 and Th22 cells were primary sources
of IL-22 (Dudakov et al., 2015). Based on RORγt expression,
it is possible to define the CD3+NK1.1−CD4+RORγt+ (mostly
Th17 and Th22 cells) subset in IHLs (Figure 3A, top). However,
we did not observe significant differences in cell numbers of
this population among three groups (Figure 3B). Moreover, a
specific NKp46+ cell subset, which expresses low levels of NK1.1
and named as NKp46+ILC22, is known to be an important
producer of IL-22 in the intestine (Sanos et al., 2009; Sciume
et al., 2012). We therefore analyzed whether those subsets could
be found in the liver. Within CD3−NK1.1low/−RORγt+CD127+
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FIGURE 1 | Inhibition of Notch signaling did not affect HBV antigens production but reduced liver injury. Mice (4 per group) were hydrodynamically injected
with saline, pHBV1.3 plasmid, or pHBV1.3 plus γ-secretase inhibitor DAPT. Mice were scarified 96 h post injection. Livers and serum were harvested for analysis.
mRNA expressions corresponding to Notch1 (A) and Notch2 (B) in the livers were measured by PT-PCR. Results are displayed as fold differences relative to the saline
injection group, and normalized to β-actin. HBsAg (C) and HBeAg (D) in the serum were measured by electro-chemiluminescence. (E) Serum ALT levels were
measured by Infinity ALT reagent. (F) IL-22 concentrations in the serum were tested by ELISA. All values are presented as the average from each group, and error
bars represent SE.
cells, three subsets can be discerned in IHLs based on
CD4 and NKp46 expression: NKp46+ILC22 (CD4−NKp46+),
CD4−ILC22 [CD4−NKp46−, CD4− lymphoid tissue inducer
(LTi)-like cells], and LTi4 (CD4+NKp46−) (Sciume et al., 2012;
Figure 3A, bottom). Total numbers of NKp46+ILC22 and LTi4
increased in the liver of mice with hydrodynamic injection
of HBV plasmids (Figures 3C,E). In contrast, CD4−ILC22
numbers reduced in response to HBV infection (Figure 3D).
DAPT administration reduced the numbers of NKp46+ILC22
(Figure 3C) and LTi4 (Figure 3E), only slightly higher than
those detected in controls. There was also a consistent trend
of elevation in the number of CD4−ILC22 with DAPT
administration, but this difference failed to achieve significant
difference (P = 0.092, Figure 3D).
Furthermore, the recruited inflammatory cells into the liver
was also determined by flow cytometry. The cell numbers
corresponding to Th cells (CD3+/CD4+, Figure 4A), CTLs
(CD3+/CD4−/NK1.1−, Figure 4B), NK cells (CD3−/NK1.1+,
Figure 4C), and NKT cells (CD3+/NK1.1+, Figure 4D)
increased in the liver of mice injected with HBV plasmid. DAPT
administration reduced the recruited numbers of Th cells, CTLs,
and NK cells with slightly higher numbers than in controls
(Figures 4A–C).
HBV Infection Induced Notch1 and Notch2
Expression in Peripheral Bloods
We then further investigated the Notch-IL-22 axis in human
peripheral bloods in vitro. Notch1 and Notch2 mRNA
expressions in the purified CD4+ T cells were investigated
by RT-PCR. Notch 1 mRNA expression did not show significant
difference between AHB and NCs, however, remarkable
increased with approximately 2-fold elevation in CHB in
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FIGURE 2 | Inhibition of Notch signaling reduced the HBV-induced elevation of IL-22, and related cytokines and chemokines mRNA expressions in the
liver. mRNA expressions corresponding to IL-22 (A), IFN-γ (B), TNF-α (C), CXCL9 (D), and CXCL10 (E) in the livers were measured by PT-PCR. Results are displayed
as fold differences relative to the saline injection group, and normalized to β-actin.
comparison with NCs (Figure 5A). Notch2 mRNA expression
were notably elevated with more than 10-fold increase in both
AHB and CHB (Figure 5B).
Inhibition of Notch Signaling Reduced HBV
Non-specific IL-22 Secretion In vitro
The purified CD4+ T cells were stimulated with either anti-
CD3 or HBV core peptides pool, in addition with Notch
signaling inhibitor DAPT for 96 h. DAPT significantly reduced
the mRNA expressions of both Hes1 and Hes5 in NCs and
HBV-infected patients (Figure S2), which indicated that DAPT
also successfully inhibited Notch signaling in vitro. IL-22 mRNA
expression and secretion were then analyzed. DAPT treatment
did not affect the IL-22 mRNA expression in CD4+ T cells
fromNCs and HBV-infected patients in both HBV-specific (HBV
peptides) and non-specific (anti-CD3) manners (Figure 6A).
Furthermore, HBV-specific IL-22 production in the supernatants
of cultured cells presented similar levels with or without
DAPT treatment (Figure 6B). However, HBV non-specific IL-
22 secretion revealed notably reduction in response to DAPT
stimulation in both NCs and HBV-infected patients (Figure 6B).
DISCUSSION
Notch signaling was proven to play a critical role in the
pathogenesis of different viral infections. The Notch ligand Dll1
regulated interferon-γ expression of CD4+/CD8+ T cells, and
positively influenced the development of anti-influenza A virus
(H1N1) immunity (Ito et al., 2011). Activation of Notch also
counteracted with Epstein-Barr virus (EBV) nuclear antigen 2
to inhibit the transcription of key protein in EBV proteins
production and the entry of EBV into lytic cycle (Rowe et al.,
2014). Repression of Notch receptors mediated the regulation
of immune response in CHB patients and the progression
to end-stage liver diseases (Trehanpati et al., 2012). In the
present study, we found that HBV infection induced Notch1
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FIGURE 3 | Inhibition of Notch signaling reduced the intrahepatic NKp46+ILC22 and LTi4 cells. (A) Populations in IHLs were discriminated based on
expression of CD3, NK1.1, CD127, RORγt, NKp46, and CD4. These included populations of CD3+CD4+NK1.1−RORγt+ (mostly Th17 and Th22 cells),
CD3−NK1.1−RORγt+CD127+NKp46+CD4− ILC22, and RORγt+CD127−NKp46− cells (CD4+ and CD4−). Representative experiments of flow cytometry is
shown. Numbers of (B) CD3+CD4+NK1.1−RORγt+ cells, (C) NKp46+ ILC22, (D) CD4− ILC22, and (E) LTi4 cells are shown. All values are presented as the average
from each group, and error bars represent SE.
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FIGURE 4 | Inhibition of Notch signaling blocked the recruitment of antigen-non-specific cells into the liver. IHLs were isolated and analyzed by flow
cytometry. (A) CD3+CD4+ cells. (B) CD3+CD4−NK1.1− cells. (C) CD3−NK1.1+ cells. (D) CD3+NK1.1+ cells. All values are presented as the average from each
group, and error bars represent SE.
FIGURE 5 | Expressions of Notch1 and Notch2 were elevated in peripheral CD4+ T cells isolated from patients with HBV infection. mRNA expressions
corresponding to Notch1 (A) and Notch2 (B) in CD4+ T cells were measured by PT-PCR. Results are displayed as fold differences relative to normal controls, and
normalized to 18sRNA. All values are presented as the average from each group, and error bars represent SE.
and Notch2 expression in peripheral blood and liver, consistent
with the previous findings of the upregulation of Notch1
expression in CD4+ T cells from CHB patients (Pei et al., 2010).
Interestingly, recent studies showed that HBVX protein activated
Notch signaling via Notch1/Notch4/Dll4 in HBV-associated
hepatocellular carcinoma (Gao et al., 2016; Kongkavitoon et al.,
2016). However, how Notch signaling regulates the downstream
pathway, which contributes to the HBV related inflammation,
was still not fully understood.
Notch signaling enhanced IL-22 production by CD4+ T cells
even in absence of STAT3 by stimulation of AhR in a ConA-
mediated acute hepatitis model in RBP-J−/− mice (Alam et al.,
2010). Our in vitro study also found a reduced expression of IL-
22 by HBV non-specific CD4+ T cells in response to blockage of
Notch signaling, but the mRNA level corresponding to IL-22 did
not change significantly. Furthermore, the in vivo study showed
that inhibition of Notch signaling did not influenceHBV antigens
production, however, reduced recruitment of inflammatory cells
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FIGURE 6 | Inhibition of Notch signaling did not affect IL-22 mRNA expression in isolated CD4+ T cells, but reduced the HBV non-specific IL-22
production in the supernatants from cultured CD4+ T cells. (A) mRNA expressions corresponding to IL-22 in CD4+ T cells were measured by PT-CPR. Results
are displayed as fold differences relative to anti-CD3 treatment, and normalized to 18sRNA. (B) IL-22 production in the supernatants were measured by ELISA. All
values are presented as the average from each group, and error bars represent SE.
into the liver and subsequent liver injury. Although DAPT
treatment did not reduced the ALT levels and IL-22 secretion in
the serum, mRNA expressions corresponding to IL-22 as well as
related inflammatory cytokines and chemokines in the liver was
significantly reduced in response to inhibition of Notch signaling.
This was partly because that IL-22-secreting cells are enriched
in the tissues but rare in peripheral bloods (Lee et al., 2012).
Thus, Notch-IL-22 axis might mainly affect the inflammation
in liver-resident, but not in peripheral bloods. This results was
also consistent with our previous finding of the proinflammatory
function of IL-22 in HBV transgenic mouse model (Zhang et al.,
2011), which revealed that Notch signaling also involved in
HBV-induced liver injury and inflammation.
We then further investigated the influence of Notch signaling
inhibition in the liver resident IL-22-secreting cells. IL-22 was
initially thought to be produced in Th17 and Th22 cells (Dudakov
et al., 2015). However, we did not find remarkable differences
in either numbers or percentages of CD4+RORγt+ cells (mostly
Th17 and Th22 cells) in the liver in response to Notch signaling
inhibition. This is partly due to the evidence in RBP-J−/− mice
that Notch-mediated IL-22 production was independent of Th17
differentiation (Alam et al., 2010). Moreover, the source of IL-22
was also expanded. ILC22, which mainly localizes in lymphoid
tissues of intestinal mucosa, secretes large amounts of IL-22
(Spits and Di Santo, 2011; Sonnenberg et al., 2011a). In the
mouse, ILC22 includes two different subsets, NKp46+ILC22 and
LTi-like cells, with distinct phenotypic markers which reflect
functional and developmental heterogeneity (Spits and Di Santo,
2011; Lee et al., 2012). NKp46+ILC22 expresses high levels of
NK cell marker NKp46, however, low or none of prototypic NK
cell marker NK1.1 (Lee et al., 2012). LTi-like cells also include
two subsets, CD4−LTi (CD4−ILC22) and CD4+LTi (LTi4) (Sawa
et al., 2010; Sonnenberg et al., 2011b). Lee et al. demonstrated that
AHR drives the development of gut NKp46+ILC22 via induction
of Notch, however, LTi cells were partially dependent on Notch
signaling (Lee et al., 2012). Herein, we firstly confirmed that all
ILC22 subsets (including NKp46+ILC22, CD4−ILC22, and LTi4
cells) could be detected in the liver of the mouse. HBV infection
induced the elevation in numbers of the NKp46+ILC22 and LTi4
cells, but reduced CD4−ILC22. Inhibition of Notch signaling
notably reduced the numbers of NKp46+ILC22 and LTi4
cells without downregulation of the HBV antigens expression.
Previous study indicated that NKp46+ILC22 expressed high
level of transcription factor T-bet, which was important for
the development and functional regulation of both NK cells
and NKp46+ILC22 (Sciume et al., 2012), however, limited
expression of T-bet was found in CD4−ILC22 and LTi4 cells.
There were few reports in the regulation and function of tissue-
resident CD4−IL-22 cells. van de Pavert et al. (2014) showed
that cell-autonomous retinoic acid signaling controlled mouse
fetal ILC3, including ILC4neg cells (CD3−CD127−α4β7+ID2+c-
Kit+CD11C−CD4−) and LTi4 cells. However, the function and
regulation of liver-resident CD4−ILC22 need to be further
elucidated. These results indicated that Notch signaling was
important in regulation of liver NKp46+ILC22 and LTi4 cells in
HBV infection, but not sufficient to directly influence virus itself
in vivo.
Due to the potential dual nature of proinflammatory and
protective roles of IL-22, we examined the predominate function
of ILC22 in the intrahepatic inflammatory response in HBV
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infection. Although the study suggested Notch-mediated IL-
22 protected RBP-J−/− mice from ConA-induced hepatitis
(Alam et al., 2010), more recent study on experimental
autoimmune uveoretinitis revealed a key pathological role
of RBP-J/Notch-induced IL-22 production in late phase of
the disease (Bhuyan et al., 2014). Furthermore, Song et al.
demonstrated NKp46+ILC3 subsets, which mainly produced
IL-17 and IL-22, promoted inflammation through granulocyte-
macrophage colony stimulating factor-induced accumulation of
inflammatory monocytes (Song et al., 2015). In this study, we
also showed that inhibition of Notch signaling reduced the
recruitment of some kinds of inflammatory cells into the liver
and ameliorated liver inflammation. This process was along
with the suppression of NKp46+ILC22 and LTi4 cells. Thus,
ILC22 may therefore contribute to the HBV induced liver disease
pathogenesis by promoting the migration of inflammatory cells
into the liver. However, IL-22 levels in the serum was not
remarkably decreased. This may partly due to the limited
numbers of hepatic ILC22, which was not enough for secreting
sufficient IL-22 to the blood stream and could only worked in the
liver resident surroundings.
In summary, we found that Notch signaling is dispensable
for HBV antigens secretion, but important in modulation of
hepatic NKp46+ILC22 and LTi4 cells, which may potentiate
the intrahepatic recruitment of antigen non-specific cells and
increase liver injury. A similar role of Notch-IL-22 axis may also
be played in the pathogenesis in patients with HBV infection. The
potential proinflammatory effect of Notch-mediated ILC22 may
be significant for the development of new therapeutic approaches
for treatment of hepatitis B.
AUTHOR CONTRIBUTIONS
Design and supervise the study: YZ and JL. Perform the
experiments: XW, JW, CQH, and XY. Enroll the patients: CQH,
LW, CXH, XB, and JL. Interpret and analyze the data: LW, CXH,
XB, JL, and YZ. Prepare the manuscript: XW, JL, and YZ.
FUNDING
This work was supported by the grants from National Natural
Science Foundation of China (81671555 and 31200650), National
Science and Technology Major Project of China (2012ZX10002-
001-006 and 2016ZX10002010-011), Wang Bao-En Research
Foundation for Liver Fibrosis in China Foundation for Hepatitis
Prevention and Control (2014016), and a grant from Tangdu
Hospital (supported YZ).
ACKNOWLEDGMENTS
We thank Dr. Michael D. Robek (Albany Medical College) for
providing the pHBV1.3 plasmid, helpful discussion, and revision
of the manuscript. We also thank Dr. Bo-Quan Jin (Department
of Immunology, Fourth Military Medical University) and Dr. Qi
Yang (Albany Medical College) for the helpful discussions.
SUPPLEMENTARY MATERIAL




Alam, M. S., Maekawa, Y., Kitamura, A., Tanigaki, K., Yoshimoto, T., Kishihara,
K., et al. (2010). Notch signaling drives IL-22 secretion in CD4+ T cells by
stimulating the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U.S.A. 107,
5943–5948. doi: 10.1073/pnas.0911755107
Bertoletti, A., and Ferrari, C. (2016). Adaptive immunity in HBV infection. J.
Hepatol. 64, S71–S83. doi: 10.1016/j.jhep.2016.01.026
Bhuyan, Z. A., Asanoma, M., Iwata, A., Ishifune, C., Maekawa, Y., Shimada,
M., et al. (2014). Abrogation of Rbpj attenuates experimental autoimmune
uveoretinitis by inhibiting IL-22-producing CD4+ T cells. PLoS ONE 9:e89266.
doi: 10.1371/journal.pone.0089266
Bitton Alaluf, M., and Shlomai, A. (2016). New therapies for chronic hepatitis B.
Liver Int. 36, 775–782. doi: 10.1111/liv.13086
Chang, J. J., and Lewin, S. R. (2007). Immunopathogenesis of hepatitis B virus
infection. Immunol. Cell Biol. 85, 16–23. doi: 10.1038/sj.icb.7100009
Cobleigh, M. A., Buonocore, L., Uprichard, S. L., Rose, J. K., and Robek, M.
D. (2010). A vesicular stomatitis virus-based hepatitis B virus vaccine vector
provides protection against challenge in a single dose. J. Virol. 84, 7513–7522.
doi: 10.1128/JVI.00200-10
Dudakov, J. A., Hanash, A. M., and van den Brink, M. R. (2015). Interleukin-
22: immunobiology and pathology. Annu. Rev. Immunol. 33, 747–785. doi:
10.1146/annurev-immunol-032414-112123
Gao, J., Xiong, Y., Wang, Y., Wang, Y., Zheng, G., and Xu, H. (2016). Hepatitis B
virus X protein activates Notch signaling by its effects on Notch1 and Notch4
in human hepatocellular carcinoma. Int. J. Oncol. 48, 329–337. doi: 10.3892/
ijo.2015.3221
Hwang, Y. Y., andMcKenzie, A. N. (2013). Innate lymphoid cells in immunity and
disease. Adv. Exp. Med. Biol. 785, 9–26. doi: 10.1007/978-1-4614-6217-0_2
Ito, T., Allen, R. M., Carson, W. F. IV., Schaller, M., Cavassani, K. A., Hogaboam,
C. M., et al. (2011). The critical role of Notch ligand Delta-like 1 in the
pathogenesis of influenza A virus (H1N1) infection. PLoS Pathog. 7:e1002341.
doi: 10.1371/journal.ppat.1002341
Kongkavitoon, P., Tangkijvanich, P., Hirankarn, N., and Palaga, T. (2016).
Hepatitis B virus HBx activates notch signaling via delta-like 4/Notch1
in hepatocellular carcinoma. PLoS ONE 11:e0146696. doi: 10.1371/
journal.pone.0146696
Lee, J. S., Cella, M., McDonald, K. G., Garlanda, C., Kennedy, G. D., Nukaya, M.,
et al. (2012). AHR drives the development of gut ILC22 cells and postnatal
lymphoid tissues via pathways dependent on and independent of Notch. Nat.
Immunol. 13, 144–151. doi: 10.1038/ni.2187
Lian, J. Q., Yang, X. F., Zhao, R. R., Zhao, Y. Y., Li, Y., Zhang, Y., et al.
(2014). Expression profiles of circulating cytokines, chemokines and immune
cells in patients with hepatitis B virus infection. Hepat. Mon. 14:e18892. doi:
10.5812/hepatmon.18892
Lok, A. S. (2016). Hepatitis B: 50 years after the discovery of Australia antigen. J.
Viral Hepat. 23, 5–14. doi: 10.1111/jvh.12444
Maekawa, Y., Minato, Y., Ishifune, C., Kurihara, T., Kitamura, A., Kojima, H.,
et al. (2008). Notch2 integrates signaling by the transcription factors RBP-J
and CREB1 to promote T cell cytotoxicity. Nat. Immunol. 9, 1140–1147. doi:
10.1038/ni.1649
Maekawa, Y., Tsukumo, S., Chiba, S., Hirai, H., Hayashi, Y., Okada, H., et al. (2003).
Delta1-Notch3 interactions bias the functional differentiation of activated
CD4+ T cells. Immunity 19, 549–559. doi: 10.1016/S1074-7613(03)00270-X
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 October 2016 | Volume 6 | Article 132
Wei et al. Notch-IL-22 Axis in HBV Infection
Maini, M. K., and Gehring, A. J. (2016). The role of innate immunity in the
immunopathology and treatment of HBV infection. J. Hepatol. 64, S60–S70.
doi: 10.1016/j.jhep.2016.01.028
Osborne, B. A., and Minter, L. M. (2007). Notch signalling during peripheral
T-cell activation and differentiation. Nat. Rev. Immunol. 7, 64–75. doi:
10.1038/nri1998
Pei, J., Tang, Z., Zang, G., and Yu, Y. (2010). Blockage of Notch1 signaling
modulates the T-helper (Th)1/Th2 cell balance in chronic hepatitis B patients.
Hepatol. Res. 40, 799–805. doi: 10.1111/j.1872-034X.2010.00680.x
Perusina Lanfranca,M., Lin, Y., Fang, J., Zou,W., and Frankel, T. (2016). Biological
and pathological activities of interleukin-22. J. Mol. Med. 94, 523–534. doi:
10.1007/s00109-016-1391-6
Radtke, F., Wilson, A., Mancini, S. J., and MacDonald, H. R. (2004). Notch
regulation of lymphocyte development and function. Nat. Immunol. 5,
247–253. doi: 10.1038/ni1045
Rowe, M., Raithatha, S., and Shannon-Lowe, C. (2014). Counteracting effects of
cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects
on virus-host interactions. J. Virol. 88, 12065–12076. doi: 10.1128/JVI.01431-14
Sanos, S. L., Bui, V. L., Mortha, A., Oberle, K., Heners, C., Johner, C., et al. (2009).
RORgammat and commensal microflora are required for the differentiation of
mucosal interleukin 22-producingNKp46+ cells.Nat. Immunol. 10, 83–91. doi:
10.1038/ni.1684
Sawa, S., Cherrier, M., Lochner, M., Satoh-Takayama, N., Fehling, H. J., Langa, F.,
et al. (2010). Lineage relationship analysis of RORgammat+ innate lymphoid
cells. Science 330, 665–669. doi: 10.1126/science.1194597
Sciumé, G., Hirahara, K., Takahashi, H., Laurence, A., Villarino, A. V., Singleton,
K. L., et al. (2012). Distinct requirements for T-bet in gut innate lymphoid cells.
J. Exp. Med. 209, 2331–2338. doi: 10.1084/jem.20122097
Song, C., Lee, J. S., Gilfillan, S., Robinette, M. L., Newberry, R. D., Stappenbeck,
T. S., et al. (2015). Unique and redundant functions of NKp46+ ILC3s
in models of intestinal inflammation. J. Exp. Med. 212, 1869–1882. doi:
10.1084/jem.20151403
Sonnenberg, G. F., Fouser, L. A., and Artis, D. (2011a). Border patrol: regulation
of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.
Nat. Immunol. 12, 383–390. doi: 10.1038/ni.2025
Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A., and Artis, D.
(2011b). CD4(+) lymphoid tissue-inducer cells promote innate immunity in
the gut. Immunity 34, 122–134. doi: 10.1016/j.immuni.2010.12.009
Spits, H., and Di Santo, J. P. (2011). The expanding family of innate lymphoid cells:
regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12,
21–27. doi: 10.1038/ni.1962
Trehanpati, N., Shrivastav, S., Shivakumar, B., Khosla, R., Bhardwaj, S.,
Chaturvedi, J., et al. (2012). Analysis of Notch and TGF-β signaling
expression in different stages of disease progression during hepatitis
B virus infection. Clin. Transl. Gastroenterol. 3:e23. doi: 10.1038/ctg.
2012.17
Tsukumo, S., and Yasutomo, K. (2004). Notch governing mature T cell
differentiation. J. Immunol. 173, 7109–7113. doi: 10.4049/jimmunol.173.
12.7109
van de Pavert, S. A., Ferreira, M., Domingues, R. G., Ribeiro, H., Molenaar, R.,
Moreira-Santos, L., et al. (2014). Maternal retinoids control type 3 innate
lymphoid cells and set the offspring immunity. Nature 508, 123–127. doi:
10.1038/nature13158
Yang, P. L., Althage, A., Chung, J., and Chisari, F. V. (2002). Hydrodynamic
injection of viral DNA: a mouse model of acute hepatitis B virus infection.
Proc. Natl. Acad. Sci. U.S.A. 99, 13825–13830. doi: 10.1073/pnas.2023
98599
Zhang, Y., Cobleigh, M. A., Lian, J. Q., Huang, C. X., Booth, C. J., Bai, X.
F., et al. (2011). A proinflammatory role for interleukin-22 in the immune
response to hepatitis B virus. Gastroenterology 141, 1897–1906. doi: 10.1053/
j.gastro.2011.06.051
Zoulim, F., Lebossé, F., and Levrero, M. (2016). Current treatments for chronic
hepatitis B virus infections. Curr. Opin. Virol. 18, 109–116. doi: 10.1016/
j.coviro.2016.06.004
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Wei, Wang, Hao, Yang, Wang, Huang, Bai, Lian and Zhang.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 10 October 2016 | Volume 6 | Article 132
